The Marley Drug business contributed $3.1 million of revenue for the quarter ended March 31, 2025 compared to $2.7 million for the quarter ended March 31, 2024. Marley Drug is a US pharmacy licensed to ship medications to all 50 states, Washington D.C. and Puerto Rico. The increase in revenue is due to a higher volume of product sold, including increased sales of ZYPITAMAG® and BRENZAVVY®, offset by lower sales of generic pharmaceutical products through both the online e-commerce platform and the legacy mail-order business.
ZYPITAMAG through insured channels contributed $519,000 of revenue for the quarter ended March 31, 2025 compared to $777,000 through insured channels for the quarter ended March 31, 2024. The decrease in revenues in 2024 can be attributed to a decrease in utilization of the product through insurance formularies, specifically Medicare Part D.
Net revenue through Gateway Pharmacy during the quarter ended March 31, 2025 was $175,000, compared to nil during the quarter ended March 31, 2024. Gateway Pharmacy was acquired by the Company on March 11, 2025; as a result, the revenue recorded during the current period was only related to product sales between March 11, 2025 to March 31, 2025. The Company intends on offering ZYPITAMAG through the pharmacy in subsequent quarters in addition to other product offerings which have increased revenue at Marley Drug.
Adjusted EBITDA for the quarter ended March 31, 2025 was $28,000 compared to $359,000 for the quarter ended March 31, 2024. Similar adjusted EBITDA for the quarter ended March 31, 2025 resulted from a decrease in AGGRASTAT revenue, a decrease revenue of ZYPITAMAG through the traditional insured channel, and higher cost of goods sold through the Marley Drug business, offset by a decrease in selling expenses, a decrease general and administrative expenses, a decrease research and development expenses, and an increase revenue through Marley Drug.
Net loss for the quarter ended March 31, 2025 was $694,000 or $0.07 per share compared to net income of $51,000 or $0.00 per share for the quarter ended March 31, 2024. The main factors contributing to the decrease in net income recorded for the quarter ended March 31, 2025 were lower AGGRASTAT revenue, a decrease revenue of ZYPITAMAG through the traditional insured channel, and higher cost of goods sold through the Marley Drug business, offset by a decrease in selling expenses, a decrease general and administrative expenses, a decrease research and development expenses, and an increase revenue through Marley Drug.
At March 31, 2025, the Company had unrestricted cash totaling $7.2 million, an increase from $6.1 million of unrestricted cash held as of March 31, 2024. Cash flows from operating activities for the quarter ended March 31, 2025 was $656,000 compared to cash used in operating activities of $132,000 for the period ended March 31, 2024.
All amounts referenced herein are in Canadian dollars unless otherwise noted.
The full financial statements are available at www.sedar.com and on the Company's website at www.medicure.com.
Notes
(1) The Company defines EBITDA as "earnings before interest, taxes, depreciation and amortization" and Adjusted EBITDA as "EBITDA adjusted for non cash and non-recurring items". The terms "EBITDA" and "Adjusted EBITDA", as it relates to the three month period ended March 31, 2025 and 2024 results prepared using IFRS, do not have any standardized meaning according to IFRS.
Conference Call Info:
Topic: Medicure's Q1 2025 Results
Call date: Thursday, May 22, 2025
Time: 7:30 AM Central Time (8:30 AM Eastern Time)
Toll Free: 1 (888) 506-0062
International: 1 (973) 528-0011
Participant Access Code: 725560
Webcast: This conference call will be webcast live over the internet at the following link: https://www.webcaster4.com/Webcast/Page/2965/52511
You may request international country-specific access information by e-mailing the Company in advance. Management will accept and answer questions related to the financial results and operations during the question-and-answer period at the end of the conference call. A recording of the call will be available following the event at the Company's website.
About Medicure Inc.
Medicure is a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug Inc. ("Marley Drug"), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug® is committed to improving access to medications for all Americans together with exceptional customer service and free home delivery. Medicure also operates Gateway Medical Pharmacy ("Gateway"), located in Portland, Oregon in a medical office building near major transportation lines and multiple healthcare clinics and centers. In addition to regular customers, the pharmacy services multiple long-term care facilities and provides non-sterile compounding services. For more information visit www.marleydrug.com. For more information about Medicure please visit www.medicure.com. For additional information about AGGRASTAT®, please visit www.aggrastat.com or refer to the full Prescribing Information. For additional information about ZYPITAMAG®, please visit www.zypitamag.com or refer to the full Prescribing Information.
To be added to Medicure's e-mail list, please visit:
http://medicure.mediaroom.com/alerts
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Information: Statements contained in this press release that are not statements of historical fact, including, without limitation, statements containing the words "believes", "may", "plans", "will", "estimates", "continues", "anticipates", "intends", "expects" and similar expressions, may constitute "forward-looking information" within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referred to as "forward-looking statements"). Forward-looking statements, include estimates, analysis and opinions of management of the Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factors beyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers are cautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others, the Company's future product revenues, expected results, including future revenue from P5P, the likelihood of receiving a priority review voucher from the United State Food and Drug Administration, expected future growth in revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approval to market the Company's products, the ability to protect its intellectual property, dependence upon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological change in the industry. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions about: general business and economic conditions; the impact of changes in Canadian-US dollar and other foreign exchange rates on the Company's revenues, costs and results; the timing of the receipt of regulatory and governmental approvals for the Company's research and development projects; the availability of financing for the Company's commercial operations and/or research and development projects, or the availability of financing on reasonable terms; results of current and future clinical trials; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing list of important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additional discussion regarding the risks and uncertainties relating to the Company and its business can be found in the Company's other filings with the applicable Canadian securities regulatory authorities or the US Securities and Exchange Commission, and in the "Risk Factors" section of its current Form 20F.
AGGRASTAT® (tirofiban hydrochloride) injection, ZYPITAMAG® (pitavastatin) tablets, and Marley Drug® are registered trademarks.
For more information, please contact:
Dr. Albert D. Friesen
Chief Executive Officer
Tel. 888-435-2220
Fax 204-488-9823
E-mail: info@medicure.com
www.medicure.com
Consolidated Statements of Financial Position
(expressed in thousands of Canadian dollars, except per share amounts)
| | | March 31, 2025 | | | December 31, 2024 | |
| Assets | | | | | | |
| Current assets: | | | | | | |
| Cash and cash equivalents | | $ | 7,216 | | | $ | 7,191 | |
| Accounts receivable | | | 4,461 | | | | 5,298 | |
| Inventories | | | 3,911 | | | | 3,282 | |
| Prepaid expenses | | | 194 | | | | 126 | |
| Total current assets | | | 15,782 | | | | 15,897 | |
| Non-current assets: | | | | | | | | |
| Property and equipment | | | 1,000 | | | | 955 | |
| Intangible assets | | | 8,964 | | | | 9,354 | |
| Goodwill | | | 3,934 | | | | 3,375 | |
| Other assets | | | 98 | | | | 98 | |
| Total non-current assets | | | 13,996 | | | | 13,782 | |
| Total assets | | $ | 29,778 | | | $ | 29,679 | |
| Liabilities and Equity | | | | | | | | |
| Current liabilities: | | | | | | | | |
| Accounts payable and accrued liabilities | | $ | 8,346 | | | $ | 7,932 | |
| Income taxes payable | | | 78 | | | | 95 | |
| Current portion of lease obligations | | | 430 | | | | 368 | |
| Acquisition payable | | | 382 | | | | - | |
| Total current liabilities | | | 9,236 | | | | 8,395 | |
| Non-current liabilities | | | | | | | | |
| Lease obligations | | | 446 | | | | 506 | |
| Total non-current liabilities | | | 446 | | | | 506 | |
| Total liabilities | | | 9,682 | | | | 8,901 | |
| Equity: | | | | | | | | |
| Share capital | | | 81,014 | | | | 81,014 | |
| Contributed surplus | | | 10,955 | | | | 10,919 | |
| Accumulated other comprehensive loss | | | (4,289 | ) | | | (4,264 | ) |
| Deficit | | | (67,585 | ) | | | (66,891 | ) |
| Total equity | | | 20,095 | | | | 20,778 | |
| Total liabilities and equity | | $ | 29,778 | | | $ | 29,679 | |
Consolidated Statements of Net Income and Comprehensive Income
(expressed in thousands of Canadian dollars, except per share amounts)
| For the three months ended March 31 | | 2025 | | | 2024 | |
| | | | | | | |
| Revenue, net | | $ | 5,484 | | | $ | 5,694 | |
| Cost of goods sold | | | 2,641 | | | | 1,797 | |
| Gross profit | | | 2,843 | | | | 3,897 | |
| | | | | | | | | |
| Expenses | | | | | | | | |
| Selling | | | 1,829 | | | | 1,974 | |
| General and administrative | | | 1,099 | | | | 1,209 | |
| Research and development | | | 570 | | | | 676 | |
| | | | 3,498 | | | | 3,859 | |
| Finance costs: | | | | | | | | |
| Finance income, net | | | (34 | ) | | | (51 | ) |
| Foreign exchange loss, net | | | 35 | | | | 7 | |
| | | | 1 | | | | (44 | ) |
| Net income (loss) before income taxes | | $ | (656 | ) | | $ | 82 | |
| | | | | | | | | |
| Income tax expense (recovery) | | | 38 | | | | (31 | ) |
| | | | | | | | | |
| Net income (loss) | | $ | (694 | ) | | $ | 51 | |
| Other comprehensive income (loss): | | | | | | | | |
| Item that may be reclassified to profit or loss | | | | | | | | |
| Exchange differences on translation of foreign subsidiaries | | | (25 | ) | | | 499 | |
| Other comprehensive income (loss), net of tax | | | (25 | ) | | | 499 | |
| Comprehensive income (loss) | | $ | (694 | ) | | $ | 550 | |
| | | | | | | | | |
| Income (loss) per share | | | | | | | | |
| Basic | | $ | (0.07 | ) | | $ | 0.00 | |
| Diluted | | $ | (0.07 | ) | | $ | 0.00 | |
Consolidated Statements of Cash Flows
(expressed in thousands of Canadian dollars, except per share amounts)
| For the three months ended March 31 | | 2025 | | | 2024 | |
| Cash (used in) provided by: | | | | | | |
| Operating activities: | | | | | | |
| Net income (loss) for the period | | $ | (694 | ) | | $ | 51 | |
| Adjustments for: | | | | | | | | |
| Current income tax expense | | | 38 | | | | 31 | |
| Amortization of property, plant and equipment | | | 114 | | | | 104 | |
| Amortization of intangible assets | | | 533 | | | | 440 | |
| Share-based compensation | | | 36 | | | | 58 | |
| Finance income, net | | | (34 | ) | | | (51 | ) |
| Unrealized foreign exchange loss | | | 35 | | | | 7 | |
| Change in the following: | | | | | | | | |
| Accounts receivable | | | 837 | | | | (479 | ) |
| Inventories | | | (585 | ) | | | (357 | ) |
| Prepaid expenses | | | (47 | ) | | | (58 | ) |
| Accounts payable and accrued liabilities | | | 415 | | | | 86 | |
| Interest received, net | | | 57 | | | | 63 | |
| Income taxes paid | | | (49 | ) | | | (27 | ) |
| Cash flows from (used in) operating activities | | | 656 | | | | (132 | ) |
| Investing activities: | | | | | | | | |
| Acquisition of intangible assets | | | - | | | | (87 | ) |
| Acquisition of Gateway Pharmacy | | | (542 | ) | | | - | |
| Cash used in investing activities | | | (542 | ) | | | (87 | ) |
| Financing activities: | | | | | | | | |
| Repayment of lease liability | | | (89 | ) | | | (76 | ) |
| Cash used in financing activities | | | (89 | ) | | | (76 | ) |
| Increase (Decrease) in cash and cash equivalents | | | 25 | | | | (295 | ) |
| Cash and cash equivalents, beginning of period | | | 7,191 | | | | 6,369 | |
| Cash and cash equivalents, end of period | | $ | 7,216 | | | $ | 6,074 | |
SOURCE: Medicure, Inc.
View the original press release on ACCESS Newswire
